Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$15.97 USD
-0.20 (-1.24%)
Updated May 20, 2024 04:00 PM ET
After-Market: $16.01 +0.04 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DAWN 15.97 -0.20(-1.24%)
Will DAWN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
BrightSpring Health announces Onco360 selected as partner for OJEMDA
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Analysts’ Top Healthcare Picks: Viridian Therapeutics (VRDN), Day One Biopharmaceuticals (DAWN)
Buy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market Entry
Buy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic Commercialization